Use of Psilocybin for Improving Health-Related Outcomes and Mental State in Patients with Major Depressive Disorder: Protocol for a Living Systematic Review and Meta-Analysis (Preprint)

A living systematic review and individual patient data meta-analysis is planned to assess the efficacy and safety of psilocybin for major depressive disorder (MDD). The review will include randomized and non-randomized trials, searching major databases and trial registries, and will analyze primary outcomes of depression severity using validated scales, with secondary outcomes including anxiety, hopelessness, quality of life, and death acceptance. Hierarchical mixed-effects models will account for clustering across studies and examine moderators like age, sex, baseline severity, prior psilocybin use, and dose. The review will be updated continuously as new evidence emerges to inform clinical practice and policy.

Study at a glance

Abstract

BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for MDD. METHODS This study will be performed as a living systematic review housed in the Nested Knowledge online platform, allowing for data extraction, analysis, and synthesis to occur on an ongoing basis as new evidence emerges. The study is registered with PROSPERO (ID: CRD42021290905) and will be compliant with Preferred Reporting Items for Systematic Review and Meta-Analysis of Individual Participant Data (PRISMA-IPD). Major databases (PubMed, Embase, SCOPUS, PyschINFO) and international clinical trials registries will be systematically searched for relevant trials. Randomized and non-randomized trials of psilocybin for the treatment of MDD will be included; authors will be contacted if individual patient data is not readily available. The three populations of interest are patients with MDD, patients with treatment-resistant MDD, and patients with MDD and life-threatening illness. The primary outcome is depression as measured by validated clinical scales (e.g., GRID-Hamilton Depression Rating Scale [GRID-HAMD], Beck Depression Inventory [BDI], Hospital Anxiety and Depression Scale - Depression Subscale [HADS-D]). Heterogeneous scale results will be transformed to z-scores and aggregated to create a composite depression outcome. Secondary outcomes include anxiety, demoralization/hopelessness, quality of life, and death acceptance. We will analyze outcome data using hierarchical mixed-effects regression models. In order to consider clustering effects from study to study, a three-level hierarchical structure will be used: the participants within each trial are considered level one, the study is level two, and the treatment group is level three. Hierarchical regressions are also conducted to examine various effect moderators of treatment outcomes, including patient age, patient sex, baseline score for a given clinical outcome, history of psilocybin use, and psilocybin dose (including the interaction of dose volume and dose schedule). All analyses will be performed on a modified intention-to-treat basis. Repeat literature searches, screening, and subsequent updates to the review will be conducted on an ongoing basis. RESULTS The initial review and subsequent updates will be published in a peer-reviewed journal and made available online via the Nested Knowledge platform. CONCLUSIONS Despite growing interest in psilocybin as a therapy for chronic, severe, or intractable MDD, there are gaps in the literature. A rapidly expanding evidence base requires a living systematic review to adequately inform clinical practice and policymaking around psychedelics for psychological and mood disorders. This meta-analysis seeks to meet that need by providing a transparent, up-to-date, and accessible living review of psilocybin for MDD.